Overview
Autoimmune interstitial keratitis (AIK) is a rare but serious condition characterized by inflammation within the corneal stroma, often leading to significant visual impairment if not promptly and effectively managed. This condition can mimic infectious keratitis, complicating both diagnosis and treatment. AIK predominantly affects younger individuals, presenting with distinctive clinical features that require careful differentiation from other inflammatory and infectious processes affecting the cornea. Understanding the nuanced presentation, diagnostic approach, and treatment strategies is crucial for optimizing patient outcomes and minimizing complications such as corneal perforation and neovascularization.
Clinical Presentation
Autoimmune interstitial keratitis typically manifests with sharply demarcated linear stromal opacities that can extend from limbus to limbus, affecting the anterior to mid-stroma predominantly. These opacities are often variable in extent and can significantly impact visual acuity. Patients frequently present with symptoms such as photophobia, foreign body sensation, and blurred vision, reflecting the severity of stromal involvement [PMID:41844187]. In more severe cases, the clinical picture can include extensive stromal infiltrates accompanied by neovascularization, indicating a refractory course that demands aggressive management [PMID:26960587]. Younger patients are disproportionately affected, highlighting the importance of early recognition and intervention to prevent long-term visual sequelae.
Diagnosis
Diagnosing AIK involves a combination of clinical evaluation and advanced imaging techniques to differentiate it from other causes of interstitial keratitis. Anterior segment optical coherence tomography (AS-OCT) plays a pivotal role by localizing the lesion primarily to the anterior stroma, providing high-resolution images that help delineate the extent of stromal involvement [PMID:41844187]. However, in vivo confocal microscopy (IVCM) offers complementary insights, revealing broader stromal activation that may not be fully captured by OCT alone, underscoring the multi-faceted nature of the inflammatory process [PMID:41844187]. Laboratory investigations, including serologic tests for autoimmune markers and ruling out infectious etiologies through cultures and PCR, are essential to support the diagnosis and guide treatment decisions.
Differential Diagnosis
Differentiating AIK from other causes of interstitial keratitis can be challenging due to overlapping clinical presentations. Infectious etiologies, such as herpes simplex virus (HSV) and varicella-zoster virus (VZV), often require exclusion through appropriate diagnostic testing, including viral cultures, PCR, and serology. Immune-mediated conditions like Mooren's ulcer and other forms of autoimmune keratitis must also be considered. The complexity in managing AIK is further compounded by the variability in response to initial treatments, as evidenced by cases where patients did not respond to acyclovir, steroids, and cyclosporine, necessitating a broader differential and tailored therapeutic approaches [PMID:26960587]. Comprehensive clinical evaluation and diagnostic workup are crucial to avoid misdiagnosis and inappropriate treatment.
Management
The management of AIK often involves a multifaceted approach aimed at controlling inflammation and preventing complications. Initial treatment frequently combines topical corticosteroids to reduce inflammation with topical antimicrobials or systemic antivirals to address potential infectious triggers, although their efficacy in AIK is limited [PMID:41844187]. In refractory cases, alternative immunosuppressive agents become necessary. One notable case highlighted the efficacy of switching to topical 0.1% tacrolimus in a 12-year-old patient who had previously failed conventional treatments including acyclovir, steroids, and cyclosporine, demonstrating significant improvement in stromal infiltrates and achieving remission lasting 9 months without recurrence [PMID:26960587]. Additionally, steroid-sparing maintenance strategies, such as the use of topical cyclosporine, have shown promise in reducing reliance on corticosteroids while maintaining therapeutic benefits [PMID:41844187]. Close monitoring and individualized treatment adjustments are essential to manage disease activity and prevent complications like corneal thinning and neovascularization.
Complications
Despite optimal management, AIK carries significant risks of severe complications that can profoundly affect visual outcomes. Corneal perforation, often associated with a relapsing course of the disease, represents one of the most critical complications, as highlighted by a case report where a patient experienced two episodes of perforation [PMID:41844187]. Other notable complications include progressive stromal thinning, which can lead to globe rupture, and neovascularization, which may further compromise corneal integrity and visual function. These complications underscore the need for vigilant follow-up and prompt intervention to manage disease flares and mitigate long-term damage.
Prognosis & Follow-up
The prognosis for patients with AIK varies widely depending on the severity of the initial presentation and the effectiveness of the treatment regimen. While visual outcomes can be favorable, with several cases achieving or maintaining corrected Snellen visual acuity of 1.0 or better, close monitoring remains indispensable [PMID:41844187]. Regular follow-up visits are crucial to detect early signs of recurrence, stromal thinning, or neovascularization, allowing for timely adjustments in therapy. Long-term management often involves a balance between controlling inflammation and minimizing immunosuppressive side effects, ensuring sustained remission and preserving visual function. Successful cases, such as the one treated with tacrolimus, demonstrate that achieving prolonged remission without recurrence is possible with appropriate individualized care [PMID:26960587].
Key Recommendations
References
1 Blaser F, Said S, Bugajska JV, Barthelmes D, Auw-Hädrich C, Zweifel S et al.. Linear Interstitial Keratitis - A Retrospective Chart Review of a Rare Entity. Klinische Monatsblatter fur Augenheilkunde 2026. link 2 Joko T, Shiraishi A, Ogata M, Ohashi Y. Therapeutic Effect of 0.1% Topical Tacrolimus for Childhood Interstitial Keratitis Refractory to Cyclosporine. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2016. link
2 papers cited of 3 indexed.